Q
QUOIN PHARMACEUTICALS LTD DRC
NASDAQ: QNRX (Quoin Pharmaceuticals, Ltd.)
Last update: 12 hours ago7.06
0.05 (0.71%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Quoin Pharmaceuticals, Ltd. | Mixed | Mixed |
AIStockmoo Score
0.5
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 7.08% |
| % Held by Institutions | 7.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Dauntless Investment Group, Llc | 30 Jun 2026 | 214,987 |
| Summittx Capital, L.P. | 30 Jun 2026 | 100,300 |
| Aberdeen Group Plc | 30 Jun 2026 | 75,000 |
| Soleus Capital Management, L.P. | 30 Jun 2026 | 72,730 |
| Birchview Capital, Lp | 30 Jun 2026 | 20,000 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |